Accession Number: | 0001714899-23-000055 |
Date: | 2023-04-12 |
Issuer: | DENALI THERAPEUTICS INC. (DNLI) |
Original Submission Date: |
SCHUTH ALEXANDER O.
C/O DENALI THERAPEUTICS INC.
161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2023-04-12 | M | 5,102 | a | $5.28 | 533,793 | indirect | ||
COMMON STOCK | 2023-04-12 | S | 5,102 | d | $25.04 | 528,691 | indirect | ||
COMMON STOCK | 2023-04-13 | M | 4,898 | a | $5.28 | 533,589 | indirect | ||
COMMON STOCK | 2023-04-13 | S | 4,898 | d | $25.04 | 528,691 | indirect | ||
COMMON STOCK | 2023-04-12 | 0 | $0.00 | 130,792 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 5.28 | 2023-04-12 | deemed execution date | M | 5,102 (d) | 2027-03-07 | common stock 5,102 | $5.28 | 93,835 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 5.28 | 2023-04-13 | deemed execution date | M | 4,898 (d) | 2027-03-07 | common stock 4,898 | $5.28 | 88,937 | direct |
ID | footnote |
---|---|
f1 | exercised shares were issued to the schuth family trust. |
f2 | the shares are held of record by the schuth family trust u/a dtd 06/05/2017, for which the reporting person serves as trustee. |
f3 | the sales reported by the reporting person were affected pursuant to a rule 10b5-1 trading plan adopted september 30, 2022. |
f4 | the sale price reported in column 4 of table i represents the weighted average sale price of the shares ranging from $25.00 to $25.49 per share. upon request by the commission staff, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price. |
f5 | the sale price reported in column 4 of table i represents the weighted average sale price of the shares ranging from $25.00 to $25.10 per share. upon request by the commission staff, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price. |
f6 | includes 119,156 rsus. |
f7 | 25% of the shares subject to the option vested on march 8, 2018 and an additional 1/48 of the shares vested monthly thereafter. |